All about health

During a late-breaking abstract presentation at the annual 2024 NKF Spring Clinical Meetings (SCM) tomorrow Dr. Dana Rizk, from the University of Alabama at Birmingham (UAB) Medical Center, will present data on the impact and safety of Fabhalta...

Satellos Bioscience Inc. ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the results of its Annual and Special...

The Kaiser Permanente Bernard J. Tyson School of Medicine (KPSOM) graduated its inaugural class of students yesterday, a milestone for the new school, which opened in July 2020. The first-ever commencement ceremony honored the Class of 2024 at the...

Incyte today announced that several abstracts featuring data from its oncology portfolio will be presented at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting held May 31 ? June 4 in Chicago, and at the European...

Lowell Farms Inc. (the "Company") , a California cannabis company with advanced distribution and production capabilities including extraction, manufacturing, sales and brand management, announces unaudited revenue and operating results for the first...

Embark Behavioral Health, a leading network of mental health treatment programs for youths and their families, debuts Summer T.I.M.E, a Virtual Therapeutic Intensive Motivational Experience. Designed to support adolescents, teenagers, and young...

Filament Health Corp.  (Cboe CA: FH) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, released its first quarter financial results and operational highlights for the period ended March 31, 2024....

Kintara Therapeutics, Inc. ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal third quarter ended March 31, 2024, and recent...

Grossman Law Offices, with its principal office in Dallas, TX, extends its concern and support to the victim involved in a motorcycle versus truck accident that occurred on March 22, 2024, around 5:30 p.m. along the Dallas North Tollway in Dallas,...

Nabla Bio (aka "Nabla"), pioneers in generative protein design, today announced the close of a $26 million Series A financing, led by Radical Ventures with participation from all existing investors, and strategic collaborations with AstraZeneca,...

With tremendous support from Canada's seven National Hockey League (NHL) teams, individuals and several communities, the ALS Super Fund has achieved a significant milestone: surpassing its first $1 million in donations through Charitable Impact's...

Perimeter Medical Imaging AI, Inc. ("Perimeter" or the "Company") ? a commercial-stage medical technology company ? today reported financial results for its first quarter ended March 31, 2024 and provided a corporate update. Adrian Mendes,...

BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the First Quarter ended March 31, 2024 and provided a corporate...

Nanopharmaceutics, Inc. , a clinical-stage pharmaceutical development company, announced the initiation of a Phase I clinical study with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University "A Phase 1 Adaptive Dose Escalation...

DermTech, Inc. (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its first-quarter 2024 financial results. First-Quarter 2024 Financial Results Billable sample volume...

Calidi Biotherapeutics Inc. ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted virotherapies, today reported its first quarter 2024 operating and financial results and reviewed recent business highlights....

ENDRA Life Sciences Inc. , a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three months ended March 31, 2024 and provided a business update. Highlights from the first quarter of 2024 and recent...

Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology ("Pulse"), today announced enhancements to its executive leadership team to support its next pivotal phase of...

Moffitt Cancer Center, a world-renowned cancer treatment and research center, and Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. and a leading nanobiotechnology company specializing in innovative cancer therapeutics, announced today a...

Nuvation Bio Inc. , a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the first quarter ended March...

Akili, Inc. , a leading digital medicine company, today reported its financial results for the quarter ended March 31, 2024 and provided an update on business progress. As announced in late April 2024, the Company's board of directors has initiated...

AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended March 31, 2024....

Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the first quarter ended...

Alto Neuroscience, Inc. ("Alto") today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress. "Our team's commitment to developing personalized therapies for the brain is exemplified by...

Expanded strategic relationship with Astellas with new research collaboration leveraging Poseida's proprietary allogeneic CAR-T platform to develop cell therapies targeting solid tumors Generated $95 million in milestone and upfront payments to-date...

Talphera, Inc. , ("Talphera"), a specialty pharmaceutical company...

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") , a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal...

VOXX International Corporation , a leading manufacturer and distributor of automotive and consumer technologies for the global markets, today announced its financial results for its Fiscal 2024 fourth quarter and year-ended February 29, 2024....

?   Pivotal Phase 2 study data of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis to be presented at the 2024 ASCO Annual Meeting as a late-breaking oral presentation on June 3rd ? ?   Company to host a conference...

Kyverna Therapeutics, Inc. , a patient-centered, clinical-stage biopharmaceutical company focused on...